- Trials with a EudraCT protocol (320)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
320 result(s) found for: Sleep Disorder.
Displaying page 7 of 16.
EudraCT Number: 2022-001563-26 | Sponsor Protocol Number: NCT05355337 | Start Date*: 2022-10-03 | |||||||||||
Sponsor Name:Region Skåne | |||||||||||||
Full Title: Pramipexole for Anhedonic Depression (PRIME-PRAXOL) | |||||||||||||
Medical condition: The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004511-29 | Sponsor Protocol Number: resgov/8nov05/01 | Start Date*: 2006-04-20 |
Sponsor Name:Barnsley Hospital NHS Foundation Trust | ||
Full Title: Pilot Study of Homeopathic Treatment of Fibromyalgia Syndrome (HOFS) | ||
Medical condition: Fibromyalgia syndrome. A chronic musculoskeletal pain disorder of unknown aetiology, characterized by widespread pain and muscle tenderness, and often accompanied by fatigue, sleep disturbance and... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001959-13 | Sponsor Protocol Number: EPICDKL5 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Adjunctive cannabidiol therapy in patients with CDKL5 deficiency disorder. Interventional drug study on efficacy and safety with focus on seizure effects | |||||||||||||
Medical condition: patients with CDKL5 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000821-29 | Sponsor Protocol Number: SPD503-401 | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab... | |||||||||||||
Medical condition: Attention-deficit/hyperactivity disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000337-40 | Sponsor Protocol Number: 42847922MDD3001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003312-65 | Sponsor Protocol Number: CL2-90098-005 | Start Date*: 2008-01-25 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, interna... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) FI (Completed) CZ (Completed) EE (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000567-77 | Sponsor Protocol Number: 42847922MDD1016 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007053-13 | Sponsor Protocol Number: STEG-CORP_111802 | Start Date*: 2009-07-31 | |||||||||||
Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K. | |||||||||||||
Full Title: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/J... | |||||||||||||
Medical condition: bladder disorder (detrusor hyperactivity caused by neurogenic disorder) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021044-17 | Sponsor Protocol Number: CLOCK_depression | Start Date*: 2010-08-11 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study. | |||||||||||||
Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001506-29 | Sponsor Protocol Number: P11-06/BF2.649 | Start Date*: 2016-06-14 | |||||||||||||||||||||||||||||||
Sponsor Name:Bioprojet | |||||||||||||||||||||||||||||||||
Full Title: DOUBLE BLIND, MULTICENTRE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE SAFETY AND EFFICACY OF PITOLISANT IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY WITH/WITHOUT CATAPLEXY, FOLLOW... | |||||||||||||||||||||||||||||||||
Medical condition: Narcolepsy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) FR (Trial now transitioned) DE (Prematurely Ended) NL (Completed) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000088-12 | Sponsor Protocol Number: D1443C00012 | Start Date*: 2008-08-18 |
Sponsor Name:Department of Psychiatry, LMU Munich | ||
Full Title: A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3) | ||
Medical condition: 40 patients with Acute Stress Disorder will be recruited within 2 years. The subjects must meet DSM- IV criteria for acute stress disorder (no acute suicidality) and will be treated with Quetiapine... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004439-36 | Sponsor Protocol Number: ACP-103-047 | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | |||||||||||||
Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease | |||||||||||||
Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008377-56 | Sponsor Protocol Number: 2008-249 | Start Date*: 2009-03-10 | |||||||||||||||||||||||||||||||
Sponsor Name:Palliativ medicinsk afdeling, Bispebjerg Hospital | |||||||||||||||||||||||||||||||||
Full Title: Melatonin for træthed og andre symptomer hos patienter med fremskreden kræft | |||||||||||||||||||||||||||||||||
Medical condition: Træthed og andre symptomer hos patienter med freskreden kræft i palliativ fase | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005627-17 | Sponsor Protocol Number: TR03 | Start Date*: 2015-12-01 | |||||||||||
Sponsor Name:Trevi Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients | |||||||||||||
Medical condition: Prurigo Nodularis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005053-22 | Sponsor Protocol Number: D1448C00007 | Start Date*: 2006-03-30 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination with ... | ||
Medical condition: Major Depressive Disorder (MDD). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) DE (Completed) CZ (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004642-92 | Sponsor Protocol Number: CL3-20098-062 | Start Date*: 2009-04-01 | |||||||||||
Sponsor Name:Laboratorios Servier S.L. | |||||||||||||
Full Title: Evaluación de la eficacia y el beneficio clínico de agomelatina (25 a 50 mg/día) durante un período de tratamiento de 6 meses en pacientes con Trastorno Depresivo Mayor.Estudio aleatorizado, doble ... | |||||||||||||
Medical condition: Trastorno Depresivo Mayor//Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000763-42 | Sponsor Protocol Number: A5361020 | Start Date*: 2008-09-05 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G... | |||||||||||||
Medical condition: Generalized Anxiety Disorder (GAD). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004315-76 | Sponsor Protocol Number: EFC16973 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | |||||||||||||
Full Title: Master protocol of two randomized, double blind, placebo-controlled, multicenter, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of ... | |||||||||||||
Medical condition: Chronic pruritus of unknown origin (CPUO) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000762-23 | Sponsor Protocol Number: A5361019 | Start Date*: 2008-09-11 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT ... | |||||||||||||
Medical condition: Generalized Anxiety Disorder (GAD). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000281-23 | Sponsor Protocol Number: Oxford University(None) | Start Date*: 2009-09-10 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Melatonin in Acute Mania Investigation (MIAMI-UK) | ||||||||||||||||||
Medical condition: Bipolar Disorder (mania and hypomania) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
